Jia Guohua, Zhou Shuimei, Xu Tangpeng, Huang Yabing, Li Xiangpan
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Department of Blood Transfusion, Zhongnan Hospital of Wuhan University, Wuhan, China.
Front Oncol. 2022 Sep 14;12:954685. doi: 10.3389/fonc.2022.954685. eCollection 2022.
The prognosis of patients with stage IIIC non-small-cell lung cancer (NSCLC) is poor due to the loss of surgical treatment opportunities. Improving the prognosis of these patients with IIIC NSCLC urgently needs to be addressed. Here, we report a stage IIIC (T4N3M0 IIIC (AJCC 8th)) NSCLC patient treated with 2 cycles of anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis therapy; after two cycles of treatment, the patient achieved a partial response and obtained the opportunity for surgical treatment. After the operation, the patient achieved a pathological complete response and successfully transformed from unresectable stage IIIC lung cancer to radical surgery (ypT0N0M0). Our study is expected to provide new ideas for treating patients with unresectable stage IIIC NSCLC in the future.
IIIC期非小细胞肺癌（NSCLC）患者由于失去手术治疗机会，预后较差。改善这些IIIC期NSCLC患者的预后是亟待解决的问题。在此，我们报告1例IIIC期（T4N3M0 IIIC（美国癌症联合委员会第8版））NSCLC患者，接受了2周期抗程序性死亡蛋白1（PD-1）免疫治疗联合化疗及抗血管生成治疗；经过2周期治疗后，患者达到部分缓解，并获得了手术治疗机会。术后，患者达到病理完全缓解，成功地从不可切除的IIIC期肺癌转变为根治性手术（ypT0N0M0）。我们的研究有望为未来治疗不可切除的IIIC期NSCLC患者提供新思路。
